Business
Agenus to Provide Fourth Quarter and Year-end 2025 Financial Report and Corporate Update
LEXINGTON, Mass., March 04, 2026--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will release its fourth quarter and year-end 2025 financial results before the market opens on Monday, March 16, 2026.
About this update from Mink Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1694,"height":353,"url":"https://media.zenfs.com/en/business-wire.com/69e23d80e2b59a9a4ff2e2ea4077f90a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/c7EeGXCbCFocsScsTJLOVw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTIwMDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/69e23d80e2b59a9a4ff2e2ea4077f90a","width":960,"height":200},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/xfgJP8k2LtkwIzbOrmF2Og--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD01MDA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/69e23d80e2b59a9a4ff2e2ea4077f90a","width":1200,"height":250}},"lazy":false},{"type":"text","content":"LEXINGTON, Mass., March 04, 2026--(BUSINESS WIRE)--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will release its fourth quarter and year-end 2025 financial results before the market opens on Monday, March 16, 2026.","length":280,"tagName":"p"},{"type":"text","content":"Agenus will host a stakeholder briefing webcast in late March to spotlight key strategic plans, data milestones and provide an update on the global botensilimab (BOT) and balstilimab (BAL) development program.","length":209,"tagName":"p"},{"type":"text","content":"About Agenus","length":12,"tagName":"p"},{"type":"text","content":"Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.","length":782,"tagName":"p"},{"type":"text","content":"About Botensilimab (BOT)","length":24,"tagName":"p"},{"type":"text","content":"Botensilimab (BOT) is a human Fc enhanced...